Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1997 Dec;52(12):1036–1039. doi: 10.1136/thx.52.12.1036

Effects of airway calibre on lung delivery of nebulised salbutamol

B J Lipworth, D J Clark
PMCID: PMC1758465  PMID: 9516895

Abstract

BACKGROUND: A study was undertaken to test the hypothesis that airway calibre may alter lung deposition and therefore lung bioavailability of inhaled drugs as a result of narrowed airways reducing peripheral drug delivery. This was evaluated using the early lung absorption profile of salbutamol over the first 30 minutes after inhalation. METHODS: Three groups were compared: (1) 10 normal subjects with mean forced expiratory volume in one second (FEV1) 109.5% predicted and mid forced expiratory flow (FEF25-75) 103.0%, (2) 10 mild asthmatic patients with FEV1 102.0% and FEF25-75 82.6%, and (3) 10 severe asthmatic patients with FEV1 49.2% and FEF25-75 27.5% predicted. Each subject had one study visit where a single dose of nebulised salbutamol was given (40 micrograms/kg) via a Ventstream nebuliser with mouthpiece followed by mouth rinsing. Plasma salbutamol levels were measured at five, 10, 20, and 30 minutes after the end of nebulisation with calculation of maximal (Cmax) and average (Cav) concentration over 0-30 minutes. Systemic beta 2 responses (plasma potassium, tremor and heart rate) and airway responses (FEV1, FEF25-75) were measured before and 30 minutes after nebulisation. RESULTS: For Cav over 0-30 minutes the severe asthmatic patients had a lower plasma salbutamol concentration (1.31 ng/ml) than either the normal subjects (2.40 ng/ml) or those with mild asthma (2.45 ng/ml): normal subjects versus severe asthmatics 95% CI 0.30 to 1.88, mild versus severe asthmatics 95% CI 0.07 to 2.21. Airway responses as delta FEF25-75 were lower in the severe asthmatic subjects (0.30 l/s) than in either the normal subjects (0.69 l/s) or those with mild asthma (0.74 l/s): normal subjects versus severe asthmatic subjects 95% CI 0.09 to 0.88, mild versus severe asthmatics 95% CI 0.04 to 0.93. Values for delta log tremor also showed attenuated responses in those with severe asthma (1.22 mg2/s) compared with normal subjects (2.00 mg2/s) or those with mild asthma (2.02 mg2/s): normal subjects versus those with severe asthma 95% CI -0.02 to 3.30, mild versus severe asthmatics 95% CI 0.02 to 3.30. CONCLUSIONS: These results show that baseline airway calibre significantly alters the early lung absorption profile of salbutamol in patients with severe asthma. This may have implications in terms of optimising dose and delivery of inhaled beta 2 agonists in these patients. 




Full Text

The Full Text of this article is available as a PDF (120.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson M. K., Curry S. H., Mills G. G., Hughes D. T. Uptake of disodium cromoglycate in obstructive airways disease. Clin Allergy. 1973 Dec;3(4):389–394. doi: 10.1111/j.1365-2222.1973.tb01346.x. [DOI] [PubMed] [Google Scholar]
  2. Chrystyn H., Corlett S. A., Silkstone V. Lung bioavailability of generic and innovator salbutamol MDIs. Thorax. 1996 Jun;51(6):658–658. doi: 10.1136/thx.51.6.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clark D. J., Gordon-Smith J., McPhate G., Clark G., Lipworth B. J. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax. 1996 Mar;51(3):325–326. doi: 10.1136/thx.51.3.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clark D. J., Lipworth B. J. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax. 1996 Oct;51(10):981–984. doi: 10.1136/thx.51.10.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clark D. J., Lipworth B. J. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol. 1996 Mar;41(3):247–249. doi: 10.1111/j.1365-2125.1996.tb00191.x. [DOI] [PubMed] [Google Scholar]
  6. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36(3):239–245. doi: 10.1007/BF00558154. [DOI] [PubMed] [Google Scholar]
  7. Lipworth B. J., Newnham D. M., Clark R. A., Dhillon D. P., Winter J. H., McDevitt D. G. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax. 1995 Jan;50(1):54–61. doi: 10.1136/thx.50.1.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lipworth B. J. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 1996 Dec;42(6):697–705. doi: 10.1046/j.1365-2125.1996.00493.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Melchor R., Biddiscombe M. F., Mak V. H., Short M. D., Spiro S. G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993 May;48(5):506–511. doi: 10.1136/thx.48.5.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Newnham D. M., Lipworth B. J. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax. 1994 Aug;49(8):762–770. doi: 10.1136/thx.49.8.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Newnham D. M., Wheeldon N. M., Lipworth B. J., McDevitt D. G. Single dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax. 1993 Jun;48(6):656–658. doi: 10.1136/thx.48.6.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pavia D., Thomson M. L., Clarke S. W., Shannon H. S. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax. 1977 Apr;32(2):194–197. doi: 10.1136/thx.32.2.194. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES